Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27422 | 0.88 | TSHR (0.60) | PLK1SMN1; SMN2ALDH1A1HAO1TSHR | |
| SCHEMBL27890905 | 0.86 | TSHR (0.57) | PLK1SMN1; SMN2ALDH1A1HAO1TSHR | |
| SCHEMBL10871834 | 0.85 | HPGD (0.55) | PLK1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL251773 | 0.83 | TSHR (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL2707464 | 0.82 | HPGD (0.56) | PLK1SMN1; SMN2ALDH1A1LMNAHAO1 | |
| SCHEMBL3640502 | 0.82 | HAO1 (0.61) | PLK1SMN1; SMN2ALDH1A1HAO1TSHR | |
| SCHEMBL23918534 | 0.81 | KDM1A (0.52) | PLK1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8487719 | 0.78 | PLK1 (0.50) | PLK1SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL2127792 | 0.78 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL5459443 | 0.78 | AKR1C3 (0.64) | SMN1; SMN2NPC1RAB9ATSHRAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129433-A1 | Diphenylamine derivatives | MERCK PATENT GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1687253-A2 | DIPHENYLAMINE DERIVATIVES | Merk Patent Gmbh (DE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051888-A2 | DIPHENYLAMINE DERIVATIVES | MERK PATENT GMBH (DE) | 2005-06-09 | — | — | WO | claimed |
| US-20070129433-A1 | Diphenylamine derivatives | MERCK PATENT GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129433-A1 | Diphenylamine derivatives | MERCK PATENT GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070123586-A1 | Nitroso derivatives of diphenylamine | MERCK PATENT GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123586-A1 | Nitroso derivatives of diphenylamine | MERCK PATENT GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123586-A1 | Nitroso derivatives of diphenylamine | NOS3, CBR3, CBR1 | PLK1 4825/4885SMN1; SMN2 1787/4885NPC1 1832/4885 |
| US-20070129433-A1 | Diphenylamine derivatives | CCNY, CHKB, CHKA | PLK1 1166/4885SMN1; SMN2 3996/4885NPC1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.